Efficacy convenience of MS treatments. Xavier Montalban Department of Neurology-Neuroimmunology. ECF Baveno 2013
|
|
- Cynthia Cummings
- 5 years ago
- Views:
Transcription
1 Efficacy convenience of MS treatments Xavier Montalban Department of Neurology-Neuroimmunology ECF Baveno 2013
2 Disclaimer Dr. Montalban has received speaking honoraria and travel expenses for scientific meetings, has been a steering committee member of clinical trials or participated in advisory boards of clinical trials in the past years with Bayer Schering Pharma, Biogen Idec, Merck Serono, Genentech, Genzyme, Novartis, Sanofi-Aventis, Teva Pharmaceuticals, GSK, Roche, Almirall, ECTRIMS, NMSS and MSIF.
3 What does patients and doctors consider? Efficacy Safety Convenience Tolerability Compliance
4 What does patients and doctors consider? Efficacy
5 DMDs (IFNs and GA) at different MS stages % reduction in ARR No clear effect on disability progression
6 Percentage of Patients Progressing Interferon beta - clinical studies Effect of IFN -1a IM on Disability over 2 Years P = 0.02 N = 301 Data Analyzed on ITT Basis (n=301) % 37% reduction in risk of progression 20 Placebo (N=143) 21.9% 10 IFN -1a IM (N=158) Weeks Jacobs et al. Ann Neurol. 1996;39:
7 Time to confirmed EDSS progression* 3 year results of the integrated data-set (BENEFIT) Confirmed EDSS Progression (%) 40 Log rank: p= Risk reduction of 40% over 3 years** (hazard ratio= 0.60) Delayed treatment 24% 10 Early IFNB-1b 16% 0 Year 1 Year 2 Year 3 Patients at risk n= n= * Main analysis without unscheduled visits ** by proportional hazards regression adjusted for T2-lesion volume
8 Early Is Better in Real Life Early treatment (<1 yr disease duration) n=2570 RRMS patients Mean follow-up: 4.5 yr Risk of not progressing Risk of not progressing 76.8% 57.4% Early treatment Delayed treatment 66.5% Early treatment Delayed treatment 40% Reduced risk of reaching EDSS 4.0 (HR=0.56) Reduced risk of reaching a EDSS progression (HR=0.63) Trojano M et al. Ann Neurol. 2007;66:
9 Proportion of patients who are still alive Time from Study Randomization to Death Early treatment with IFNβ-1b 50 µg was associated with a 47% reduction in the hazard ratio for all-cause mortality over 21 years compared with initial placebo treatment 100% 95% 90% IFNB-1b 50 µg Placebo 85% 80% 75% At risk: IFNB-1b 50 µg Placebo 70% 65% HR=0.535 (95% CI: ) 46.5% reduction in hazard ratio Log rank, P= Time (Years) Goodin et al. Neurology 2012
10 1000 CIS: Barcelona CIS inception cohort Mar Tintoré, Àlex Rovira, Jordi Río, Susana Otero, Georgina Arrambide, Carmen Tur, Manuel Comabella, Carlos Nos, Laura Negrotto, Ingrid Galán, Angela Vidal-Jordana, Joaquim Castilló, Filipe Palavra, Eva Simón, Raquel Mitjana, Cristina Auger, Jaume Sastre-Garriga, Xavier Montalban Centre d Esclerosi Múltiple de Catalunya (Cemcat) and MR Unit Departments of Neurology-Neuroimmunolgy and Radiology Hospital Universitari Vall d Hebron Universitat Autònoma de Barcelona ECTRIMS 2013
11 Patients and methods Inception cohort of patients with CIS started in 1995-ongoing Cemcat Department of Neuroimmunology Neurorehabilitation Unit Clinical session
12 Patients and methods Inclusion criteria: Age < 50 years Entry window: 3 months from disease onset Follow-up visits: Clinical assessment every three to six months: relapses and EDSS Radiological assessment: MRI at baseline, 3-6 m, 12 m and every 5 years OB IgG: agarose IEF+immunoblotting Remnant CSF and serum samples: stored at -80 C Informed consent
13 Results: CDMS multivariate Gender HR 1 ( ) Age cat HR 1.4 ( ) HR 1.7 ( ) HR 1.9 ( ) Topography HR 0.9 ( ) Oligoclonal bands HR 1.5 (1.1 2) Barkhof criteria HR 3.6 ( ) HR 6.6 ( ) Treatment HR 0.6 ( )
14 Results: EDSS3 multivariate Gender HR 0.7 ( ) Age cat HR 0.7 ( ) HR 0.6 ( ) HR 0.8 ( ) Topography HR 0.6 ( ) Oligoclonal bands HR 2.3 ( ) Barkhof criteria HR 0.8 ( ) HR 2.4 ( ) Treatment HR 0.5 ( )
15 Conclusions Early treatment decreases the risk of conversion to CDMS and accumulation of disability
16 Annualized Relapse Rate (95% CI) Natalizumab Annualized Relapse Rate P< Year % 0.78 P< % Placebo n=315 Natalizumab n= P< Year 0-1 Year % FDA per subject mean relapse rate at 2 years = 0.67 for placebo and 0.22 for natalizumab (67% reduction)
17 Proportion With Sustained Progression Natalizumab Progression of Disability 0.4 Hazard Ratio (HR)=0.58 (95% CI: 0.43, 0.77) 0.3 P= Placebo 29% 42% Natalizumab 17% Weeks
18 Mean Number of Gd+ Lesions Natalizumab Number of Gd-enhancing lesions P< Placebo n=315 Natalizumab n= % 92% At Year 1 At Year 2
19 Freedoms (phase III trial): Primary Endpoint Annualized Relapse Rate Kappos L et al. NEJM 2010
20 Annualized relapse rate TRANSFORMS (phase III trial): Primary Outcome - Annualized Relapse Rate % vs IFNβ-1a p < % vs IFNβ-1a p = IFNβ-1a IM (n = 431) Fingolimod 0.5 mg (n = 429) Fingolimod 1.25 mg (n = 420) Intent-to-treat population Negative binomial regression model adjusted for treatment group, country, baseline number of relapses in previous 2 years and baseline Expanded Disability Status Scale as covariates; confirmed relapses; p = for fingolimod 0.5 vs 1.25 mg IFNβ-1a IM, interferon β-1a intramuscularly Cohen J et al. NEJM 2010
21 FREEDOMS and TRANSFORMS clinical outcomes: improvement relative to control Outcome FREEDOMS 2-year placebo control TRANSFORMS 1-year IFNβ-1a, IM control ARR ( ) 54%*** 52%*** Time to relapse, HR ( ) 52%*** 48%*** Proportion relapse-free ( ) 49%*** 18%*** Time to disability progression, 3 month, HR ( ) 30%* 29% Time to disability progression, 6 month, HR ( ) MSFC mean difference, z-score ( ) 37%** * 0.02* Data shown are for fingolimod 0.5 mg; *p 0.05; **p 0.01; ***p ARR, annualised relapse rate; HR, hazard ratio; IFN, interferon; IM, intramuscular; MSFC, Multiple Sclerosis functional composite
22 Mean (SD) lesion number Mean (SD) lesion number FREEDOMS: inflammatory disease activity Number of new/enlarging T 2 lesions, Months 0 to 24 Number of T 1 Gd+ lesions at Month 24 p< p< p< (13.2) p< % (2.4) 8 2 % 2 0 Placebo (n = 339) 2.5 (7.2) Fingolimod 0.5 mg (n = 370) 2.5 (5.5) Fingolimod 1.25 mg (n = 337 ) Placebo (n = 332) 0.2 (0.8) Fingolimod 0.5 mg (n = 369) 0.2 (1.1) Fingolimod 1.25 mg (n = 343 ) Gd+, gadolinium-enhanced; SD, standard deviation Kappos L et al. N Engl J Med 2010
23 Clinical trials forthcoming drugs Drug Trial n T2 Gd Relapses Progression BG-12 BID (vs placebo) BG-12 BID (vs placebo, GA) Teriflunomide (7-14mg vs placebo) Teriflunomide (7-14mg vs placebo) Laquinimod (vs placebo) Laquinimod (vs placebo, IFN) Alemtuzumab (vs IFN Beta 1a) Alemtuzumab (vs IFN Beta 1a) DEFINE % -90% -53% -38% CONFIRM % -74% -44% ns TEMSO % -80% -31% -30% TOWER % -31.5% ALLEGRO % -37% -23% -49% BRAVO % ns ns -40% CAREMS-I % -63% -54% ns CAREMS-II % -61% -49% -42%
24 Annualized relapse rates observed in the 26 MS trials against the publication year The size of the bubble indicates the size of the trial and is proportional to the sample size. The solid line shows the model values of the negative binomial regression and the dashed lines indicate 95% confidence intervals. 24 Nicholas et al, Mult Scler. 2011;17:
25 Atrophy Brain atrophy occurs at a faster rate in people with MS than in healthy controls Brain atrophy correlates with and predicts disability Some drugs have shown positive effects on global atrophy When included in a multivariate model, relapses and PBVC remained as independent contributors to the treatment effect on disability progression
26 Clinical trials - atrophy results licensed drugs (<2013) TRIAL Form Drug Reported results ETOMS CIS IFN Positive BENEFIT CIS IFN Negative CHAMPS CIS IFN Not reported PRECISE CIS GA Negative Pivotal Betaferon RRMS IFN Not reported PRISMS RRMS IFN Not reported Pivotal Avonex RRMS IFN Negative Eu-Can Copaxone RRMS GA Positive* AFFIRM RRMS NTZ Negative FREEDOMS I & II RRMS FTY Positive TRANSFORMS RRMS FTY Positive EUSPMS SPMS IFN Negative IMPACT SPMS IFN Not reported SPECTRIMS SPMS IFN Not reported PROMISE PPMS GA Negative Barcelona DBPC PPMS IFN Negative London DBPC PPMS IFN Negative *Reanalysis
27 Clinical trials atrophy results forthcoming drugs Drug Trial n T2 Gd Relapses Progression Atrophy reduction BG-12 BID (vs placebo) BG-12 BID (vs placebo, GA) DEFINE % -90% -53% -38% -30% CONFIRM % -74% -44% ns -21% (ns) Teriflunomide (7-14mg vs placebo) TEMSO % -80% -31% -30% BPF, GM (ns) WM 164% (p=0.002) Teriflunomide (7-14mg vs placebo) Laquinimod (vs placebo) Laquinimod (vs placebo, IFN) Alemtuzumab (vs IFN Beta 1a) Alemtuzumab (vs IFN Beta 1a) TOWER % -31.5% ALLEGRO % -37% -23% -49% -33% BRAVO % ns ns -40% -27% CAREMS-I % -63% -54% ns -42% CAREMS-II % -61% -49% -42% -23%
28 What does patients and doctors consider? Efficacy Safety
29 What does patients and doctors consider? Efficacy Safety Convenience
30 Convenience Convenient procedures are those intended to increase ease in accessibility, save resources (such as time, effort and energy) and decrease frustration. Convenience is a relative concept, and depends on context
31 PATIENTS and DOCTORS MAY CONSIDER: CONVENIENCE
32 Injection anxiety or phobia Prevalence rates of injection-related anxiety significant enough to prevent selfinjection may be as high as 50% for some types of injections (Mohr et. al., 2001)
33 PATIENTS and DOCTORS MAY CONSIDER: CONVENIENCE Increase compliance Apparently more convenient that s.c. Lost of working days
34 PATIENTS and DOCTORS MAY CONSIDER: CONVENIENCE Much more convenient In theory, less compliance
35 Patients May Prefer Oral, Rather Than Injectable, Treatments in Chronic Disease??? In a survey of patient preference for a new oral or injectable medication for type 2 diabetes, the majority of respondents preferred the oral treatment option 2402 patients responded to the survey. Significantly more patients preferred the oral treatment option in each scenario (p<0.001) Dibonaventura MD et al. Patient Prefer Adherence 2010;4:
36
37 PATIENTS and DOCTORS MAY CONSIDER: CONVENIENCE Complexity of treatment: Safety controls by other specialists and other tests Lost of working days
38 What does patients and doctors consider? Efficacy Safety Convenience Tolerability Compliance
39 Definitions of Adherence and Persistence Adherence (or compliance*) 1 The extent to which patients take medications as prescribed (i.e. the correct dose at the correct times) Persistence 2 The extent to which patients continue taking medications over time Adherence can be measured 1 Directly, using blood serum or urine levels of the drug or its metabolite(s) Indirectly, using patient self-reports, pill counts, or prescription claims * Adherence is preferred to compliance because it recognises the therapeutic alliance between the patient and the physician * Adherence is preferred to compliance because it recognises the therapeutic alliance between the patient and the physician 1. Osterberg L et al. N Engl J Med 2005;353: ; 2. Cramer JA et al. Value Health 2008;11:44 47.
40 The Global Adherence Project (GAP): Reasons for Non-adherence Injection/tolerability factors Patient factors Other 32% of patients: at least one injectionrelated reason 84% of patients: other various reasons Patients may report more than one reason N=2648. Devonshire V et al. Eur J Neurol 2011;18:69 77
41 Respect for their choice
42 Respect for their choice
43
44 Kasper et al. Eur J Neurol 2008 The DA consisted of a comprehensive evidence-based MS patient information booklet about immunotherapy options and an interactive worksheet
45 Kasper et al. Eur J Neurol 2008 Treatment choices: no differences were found between groups.
46 Kasper et al. Eur J Neurol 2008 Providing patients with balanced information may not be sufficient to alter the decision-making process
47 Estimated PML incidence stratified by the three risk factors of anti-jcv antibody serostatus, prior immunosuppressant use, and natalizumab treatment duration Tur et al. MSJ 2012
48 Classification of patients treated with natalizumab according to their risk of developing PML (CEM-Cat Jul 2011) 100% 100% 100% 76% 40% Patients who continue treatment after being informed of the JCV test results Tur et al. MSJ 2012
49 Shared decision making Patient Experiences Values and Preferences SDM INTERACTION Family, Society Clinician Treatment Options Potential benefits, harms, outcomes Shared decision making combines the measurement of patient preferences with evidence-based practice
50 OTHER ASPECTS: PATIENTS OPINION, MEDIA, SOCIAL NETWORKS
51 DMF s uptake in the first week of launch in US
52 COST
53 Key Points The field of MS therapy is changing rapidly Newer therapies may supplant currently available DMDs mainly in new patients The newer therapies will have both known and unforeseen complications Future treatment options will be far more complex than those currently available to us Budgetary constraints will play a major role in the decision making process
54 MRI
The invisible facets of MS and everyday challenges clinician s perspective. Mar Tintore
The invisible facets of MS and everyday challenges clinician s perspective Mar Tintore Centre d Esclerosi Múltiple de Catalunya (Cemcat). Department of Neurology/Neuroimmunology Hospital Universitari Vall
More informationEAN Amsterdam June 23-27, 2017
EAN 2017 Amsterdam June 23-27, 2017 MS Nowadays-new goals Giancarlo Comi Dept. of Neurology & Institute of Experimental Neurology Università Vita Salute S.Raffaele, Milano European Charcot Foundation Disclosure
More informationMS Academia: Multiple sclerosis advanced course
6 October 2015 - Barcelona, Spain MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Mark S. Freedman University of Ottawa and the Ottawa
More information2013 MS Phenotype Descriptions: Relapsing MS 1
2013 MS Phenotype Descriptions: Relapsing MS 1 Disease-Modifying Therapies? which can be found in its entirety at. Clinically isolated syndrome (CIS) Not Active a Active a,b Relapsing-remitting disease
More informationProgress in the field
Progress in the field Eva Havrdová Charles University in Prague 1st Medical Faculty and General University Hospital Disclosures Dr. Havrdová has received consulting fees from Actelion, Biogen Idec, Merck,
More information1996 vs 2013 MS Phenotype Descriptions of Progressive Disease
Learning Objectives Upon completion, participants should be able to: Describe methods of distinguishing among RRMS, SPMS, and PPMS Incorporate available evidence about emerging and recently approved novel
More informationSpinal cord MR imaging in Multiple Sclerosis
43ème CONGRÈS ANNUEL de la Société Française de NeuroRadiologie 30 mars au 1 er avril 2016 Novotel Paris Tour Eiffel Spinal cord MR imaging in Multiple Sclerosis Àlex Rovira Unitat de Neurorradiología.
More informationClinician s view of Benefit-Risk
Clinician s view of Benefit-Risk Gordon Francis, MD Novartis, Clinical Development Clinician s View of Benefit-Risk: a need for reliable metrics A tale of 3 drugs Natalizumab MS Crohn s Disease Fingolimod
More informationAdherence in multiple sclerosis: Neurologist s view
Adherence in multiple sclerosis: Neurologist s view Jaume Sastre-Garriga Unitat de Neuroimmunologia Clínica Centre d Esclerosi Múltiple de Catalunya CEMCat Hospital Universitari Vall d Hebron, Barcelona
More informationAdvances in the Management of Multiple Sclerosis: A closer look at novel therapies. Disclosures
Advances in the Management of Multiple Sclerosis: A closer look at novel therapies Lily Jung Henson, MD, MMM, FAAN Chief of Neurology Piedmont Healthcare, Atlanta, GA National Association of Managed Care
More informationMS Academia: Multiple sclerosis advanced course
13 September 2016 - London, UK MS Academia: Multiple sclerosis advanced course IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org Robert J. Fox Assessment of treatment response IMPROVING
More informationClinical and research application of MRI in diagnosis and monitoring of multiple sclerosis
24-25 February 2016 - Siena, Italy Clinical and research application of MRI in diagnosis and monitoring of multiple sclerosis IMPROVING THE PATIENT S LIFE THROUGH MEDICAL EDUCATION www.excemed.org What
More informationTRANSPARENCY COMMITTEE Opinion 05 March 2014
The legally binding text is the original French version TRANSPARENCY COMMITTEE Opinion 05 March 2014 AUBAGIO 14 mg, film-coated tablet B/28 tablets (CIP: 3400927499890) Applicant: GENZYME SAS INN ATC code
More informationCommittee Approval Date: December 12, 2014 Next Review Date: December 2015
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 12, 2014 Next Review Date: December 2015 Effective Date: January
More informationPatient 1: 31-Year-Old Female. Fingolimod treatment
Cell Counts (10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Cell Count ( 10 9 /L) Lymphocyte Pharmacodynamics and Safety of Use in Patients Previously
More informationGiancarlo Comi, M.D. On Behalf of the MS-LAQ-301 (ALLEGRO) Study Group. Assessment of oral laquinimod in preventing progression of Multiple Sclerosis
COMPARISON OF EARLY AND DELAYED ORAL LAQUINIMOD IN PATIENTS WITH RELAPSING- REMITTING MULTIPLE SCLEROSIS: EFFECTS ON DISABILITY PROGRESSION AT 36 MONTHS IN THE ALLEGRO TRIAL Giancarlo Comi, M.D. On Behalf
More informationAssessing treatment outcomes in multiple sclerosis trials and the clinical
1 Assessing treatment outcomes in multiple sclerosis trials and the clinical setting Working title: Outcomes in multiple sclerosis Carmen Tur 1, Marcello Moccia 1,2, Frederik Barkhof 1,3,4,5, Jeremy Chataway
More informationMS Trust Comments on the ACD
MS Trust Comments on the ACD Name xxxxxxxxxxx Role other Other role xxxxxxxxxxxxxxxxxx Location England Conflict no Notes Comments on individual sections of the ACD: Section 1 The MS Trust maintains that
More informationActivity presentations are considered intellectual property.
Activity presentations are considered intellectual property. Activity presentations are considered intellectual property and are for viewing purposes only. No content should be copied or reproduced in
More informationThe Effects of Daclizumab High Yield Process (DAC HYP) on Patient Centered Functional Outcomes: Results From the DECIDE Study
2015 Annual Meeting of the Consortium of Multiple Sclerosis Centers May 27 30, 2015 Indianapolis, IN The Effects of Daclizumab High Yield Process () on Patient Centered Functional Outcomes: Results From
More informationWorkshop II. How to manage highly active MS patients in practice?
Workshop II How to manage highly active MS patients in practice? Gavin Giovannoni Department of Neurology Institute of Cell and Molecular Science Queen Mary University London & Barts and The London NHS
More informationBenefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints
Benefit/Risk Strategies in Selecting Therapeutic Solutions for MS: HCP and Patient Viewpoints 1 Learning Objectives Review the benefit/risk strategies in selecting therapy for MS patients while assessing
More informationMRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis. E.W. Radue K. Bendfeldt Till Sprenger
MRI in Multiple Sclerosis Features of Cerebral Atrophy with special focus on Multiple Sclerosis E.W. Radue K. Bendfeldt Till Sprenger Medical Image Analysis Center University Hospital Basel www. miac.ch
More informationNeurofilament light chain level is a weak risk factor for the development of MS
ARTICLES Neurofilament light chain level is a weak risk factor for the development of MS Georgina Arrambide, MD, PhD* Carmen Espejo, PhD* Herena Eixarch, PhD Luisa M. Villar, PhD José C. Alvarez-Cermeño,
More informationPer Soelberg Sørensen
Per Soelberg Sørensen Danish Multiple Sclerosis Center Department of Neurology Rigshospitalet, University of Copenhagen Copenhagen, Denmark Declared receipt personal compensation for serving on scientific
More informationMedication Policy Manual. Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012
Medication Policy Manual Policy No: dru283 Topic: Aubagio, teriflunomide Date of Origin: November 9, 2012 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationEfficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials
RESEARCH ARTICLE Efficacy of delayed-release dimethyl fumarate in relapsing-remitting multiple sclerosis: integrated analysis of the phase 3 trials Vissia Viglietta 1, David Miller 2, Amit Bar-Or 3, J.
More informationMitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA
Mitzi Joi Williams, MD Neurologist MS Center of Atlanta Atlanta, GA Disclosures Consultant and Speaker Bureau member for Biogen-Idec, Pfizer, TEVA Neuroscience, Bayer, EMD Serrono, Questcor, Novartis,
More informationPositive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine
Media Release Basel 21 December 2016 Positive Phase III results for Roche s investigational medicine OCREVUS (ocrelizumab) published in New England Journal of Medicine OCREVUS is the first and only investigational
More informationBruce Cree, MD, PhD, MCR. BG-12 Has Shown Nrf2 Pathway. Activation. DEFINE (BG-12/Dimethyl Fumarate) : Study Design
MS Therapies Update 212 Bruce Cree, MD, PhD, MCR BG12 Alemtuzumab Daclizumab BAF312 Erythropoetin Outline Fingolimod IFN β-1a Natalizumab Oral solumedrol Duloxetine O BG-12 Has Shown Nrf2 Pathway O OH
More informationCSF Axonal Injury Markers
CSF Axonal Injury Markers Gavin Giovannoni Barts and The London Disclosures Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical trial design,
More informationUpdate in Multiple Sclerosis
Update in Multiple Sclerosis Kyle Smoot, MD Providence MS Center Portland, OR 1 Disclosures Research funds from Biogen. Consulting fees from Acorda, Biogen, EMDSerono, Genzyme, Novartis, and Teva. 2 Outline
More informationAnisha Keshavan. Roland Henry, PhD. Proportion of Patients (%) Rituximab 2000mg (n=66) Placebo (n=35)
Two Faces of Multiple Sclerosis February 8, 217 5 T H A N N U A L R E C E N T A D V A N C E S I N N E U R O L O G Y B CELL THERAPY FOR MULTIPLE SCLEROSIS: A NEW DAY? Inflammation Relapsing MS Anisha Keshavan
More informationEvidence from bone marrow transplantation
Evidence from bone marrow transplantation Gianluigi Mancardi Department of Neuroscience, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health, Ospedale Policlinico San Martino, University
More informationPediatric MS treatments: What do you start with, when do you switch?
Pediatric MS treatments: What do you start with, when do you switch? Tim Lotze, M.D. Associate Professor of Pediatric Neurology Texas Children s Hospital Baylor College of Medicine Disclosures Clinical
More informationBiothérapies et risques infectieux en. neurologie
Biothérapies et risques infectieux en Lieu 14 Date neurologie Patrick Vermersch CHU de Lille XXIIe Journée Régionale de Pathologie Infectieuse Lille, 13 octobre 2015 Liens d intérêts Honoraires, Congrés,
More informationCost-effectiveness of cladribine (Mavenclad ) for the
Cost-effectiveness of cladribine (Mavenclad ) for the treatment of adult patients with highly active relapsing multiple sclerosis (MS) as defined by clinical or imaging features The NCPE has issued a recommendation
More informationA Glimpse at Immunomodulators in MS
A Glimpse at Immunomodulators in MS An Interview with Mark S. Freedman, HBSc, MSc, MD, CSPQ, FAAN, FRCPC Multiple Sclerosis Research Unit, University of Ottowa, Ottowa Canada Ottawa Hospital Research Institute,
More informationSwitching from natalizumab to fingolimod: an observational study
Acta Neurol Scand 2013: 128: e6 e10 DOI: 10.1111/ane.12082 Ó 2013 John Wiley & Sons A/S ACTA NEUROLOGICA SCANDINAVICA Clinical Commentary Switching from natalizumab to fingolimod: an observational study
More informationProgressive Multiple Sclerosis
Progressive Multiple Sclerosis Definitions, Clinical Course and Emerging Therapies M. Mateo Paz Soldán, MD, PhD Neurology Service, VA Salt Lake City HCS Assistant Professor of Neurology, University of
More informationLong-term effects of cladribine tablets on MRI activity outcomes in patients with relapsing remitting multiple sclerosis: the CLARITY Extension study
753365TAN0010.1177/1756285617753365Therapeutic Advances in Neurological DisordersG Comi, S CooK research-article2018 Therapeutic Advances in Neurological Disorders Original Research Long-term effects of
More informationConsortium of Multiple Sclerosis Centers 2015 Abstract #3485
Alemtuzumab (ALE) Improves Disability After Switch from Other Disease Modifying Therapies in a High Disability, Treatment Refractory Relapsing MS Cohort Consortium of Multiple Sclerosis Centers 2015 Abstract
More informationLife Long Brain Health and DMT Comparative Effectiveness
Life Long Brain Health and DMT Comparative Effectiveness Timothy Vollmer, MD Professor of Neurology University of Colorado Denver Medical Director- RMMSC and Co-Director Rocky Mountain MS Center at CU
More informationMULTIPLE SCLEROSIS - REVIEW AND UPDATE
MULTIPLE SCLEROSIS - REVIEW AND UPDATE Luka Vlahovic, MD Neuroimmunology/Multiple Sclerosis Creighton University Medical Center MS is primary demyelinating disease of the central nervous system. MS is
More informationA comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo
Original Research Paper A comparison of multiple sclerosis disease activity after discontinuation of fingolimod and placebo Patrick Vermersch, Ernst-Wilhelm Radue, Norman Putzki, Shannon Ritter, Martin
More informationMultiple Sclerosis: Emerging Therapies
Multiple Sclerosis: Emerging Therapies Bruce Cree, MD, PhD, MCR Conflicts of Interest EMD Serono: Grant support ovartis: Adviser, Clinical Trial Participant What are the Future Considerations for MS Therapies?
More informationHot Topics Multiple Sclerosis. Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018
Hot Topics Multiple Sclerosis Natalie Parks, MD, FRCPC Assistant Professor, Dalhousie University June 27, 2018 Disclosures Natalie Parks has received compensation from Biogen, EMD Serono, Roche, and Sanofi
More informationTop 10 Research Findings of 2016
Top 10 Research Findings of 2016 NMSS Regional Summit 2017 June 10, 2017 Rebecca Spain, MD, MSPH VA Portland Health Care System Oregon Health & Science University Disclosures Research support: NMSS Department
More informationTreating MS patients earlier in the disease progression may affect long-term outcomes 1-4
Treating MS patients earlier in the disease progression may affect long-term outcomes 1-4 TIME DISEASE ONSET EARLY TREATMENT NATURAL COURSE OF MS LATER TREATMENT DISABILITY INCREASE The disease activity
More informationAuthor s Accepted Manuscript
Author s Accepted Manuscript Optimizing therapy early in multiple sclerosis: an evidence-based view Tjalf Ziemssen, Nicola De Stefano, Maria Pia Sormani, Bart Van Wijmeersch, Heinz Wiendl, Bernd C. Kieseier
More informationInnovazione e personalizzazione nella terapia della SM. Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila
Innovazione e personalizzazione nella terapia della SM Rocco Totaro Centro per la Diagnosi e Cura delle Malattie Demielinizzanti L Aquila Which are the objectives of MS treatment? «Historically»
More informationKeywords Multiple sclerosis. Fingolimod. Real-world evidence. Benefit risk profile. Observational study ORIGINAL ARTICLE
Neurotherapeutics (2018) 15:190 199 https://doi.org/10.1007/s13311-017-0595-y ORIGINAL ARTICLE Clinical and Demographic Profile of Patients Receiving Fingolimod in Clinical Practice in Germany and the
More informationNatalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two Italian MS Centers
Neurol Ther (2015) 4:147 157 DOI 10.1007/s40120-015-0038-9 ORIGINAL RESEARCH Natalizumab Discontinuation and Treatment Strategies in Patients with Multiple Sclerosis (MS): A Retrospective Study from Two
More informationRisk attitudes and risk perceptions in individuals with multiple sclerosis
Original Article Risk attitudes and risk perceptions in individuals with multiple sclerosis Bonnie I Glanz, Emily Greeke, Allison LaRussa, Fiona Stuart, David J Rintell, Tanuja Chitnis and Brian C Healy
More informationReal-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis
Open Access pissn 1738-6586 / eissn 2005-5013 / J Clin Neurol 2018 ORIGINAL ARTICLE Real-World Effectiveness of Disease-Modifying Therapies in Korean Patients with Relapsing Multiple Sclerosis Su-Hyun
More informationLe Hua, MD. Disclosures Teaching and Speaking: Teva Neurosciences, Genzyme, Novartis Advisory Board: Genzyme, EMD Serono
Le Hua, MD Le Hua, MD, is a staff neurologist at Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, NV. She is involved in clinical trials assessing new therapies for the treatment of MS and
More informationMEDIA BACKGROUNDER. Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS)
MEDIA BACKGROUNDER Teriflunomide: A novel oral drug being investigated for the treatment of Multiple Sclerosis (MS) 1. Background Teriflunomide is a new oral disease-modifying therapy (DMT), discovered
More informationMultiple Sclerosis (MS) is a
The role of interferon beta in multiple sclerosis management David J Rog MRCP, John P Mottershead MRCP, Greater Manchester Neurosciences Centre, Hope Hospital, Stott Lane, Manchester, M6 8HD SPL Multiple
More informationLaquinimod Therapy in Multiple Sclerosis: A Comprehensive Review
DOI 10.1007/s40120-014-0017-6 REVIEW Laquinimod Therapy in Multiple Sclerosis: A Comprehensive Review Channa Kolb-Sobieraj Sahil Gupta Bianca Weinstock-Guttman To view enhanced content go to www.neurologytherapy-open.com
More informationPresented at the Annual Congress of ECTRIMS, October 11, 2018, Berlin, Germany
Final Results of a Placebo Controlled, Phase 2 Multicenter Study of Ublituximab (UTX), a Novel Glycoengineered Anti-CD20 Monoclonal Antibody (mab), in Patients with Relapsing Forms of Multiple Sclerosis
More informationCurrent & Emerging Treatment & Novel Strategies in the Management of MS
Current & Emerging Treatment & Novel Strategies in the Management of MS Dr Shiv Saidha, MD, MRCPI Assistant Professor of Neurology, Johns Hopkins University School of Medicine Disclosures Dr. Saidha receives
More informationTechnology appraisal guidance Published: 28 May 2014 nice.org.uk/guidance/ta312
Alemtuzumab for treating relapsing-remitting multiple sclerosis Technology appraisal guidance Published: 28 May 2014 nice.org.uk/guidance/ta312 NICE 2017. All rights reserved. Subject to Notice of rights
More informationBiologics and Beyond: Treatment of Multiple Sclerosis. Rita Jebrin, PharmD, BCPS
Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS Disclosure Information Biologics and Beyond: Treatment of Multiple Sclerosis Rita Jebrin, PharmD, BCPS I have no financial
More informationPATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M / F Year Month Day
Applicant must be covered on an Alberta Government sponsored drug program. Page 1 of 6 PATIENT INFORMATION: Patient Surname First Name Middle Initial Sex Date of Birth Alberta Personal Health Number M
More informationTechnology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493
Cladribine tablets for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 6 December 2017 nice.org.uk/guidance/ta493 NICE 2018. All rights reserved. Subject to Notice
More informationClinical Study Synopsis
Clinical Study Synopsis This Clinical Study Synopsis is provided for patients and healthcare professionals to increase the transparency of Bayer's clinical research. This document is not intended to replace
More informationNeuroimaging and Other Biomarkers. MRI for Diagnosis, Prognosis and Treatment Decisions in MS
Neuroimaging and Other Biomarkers MRI for Diagnosis, Prognosis and Treatment Decisions in MS Eric Klawiter, MD MSc Massachusetts General Hospital May 30, 2014 Disclosures and Funding Disclosures: Consulting
More informationMULTIPLE SCLEROSIS IN Managing the complexity of multiple sclerosis. Olga Ciccarelli and Alan Thompson
MULTIPLE SCLEROSIS IN 2015 Managing the complexity of multiple sclerosis Olga Ciccarelli and Alan Thompson The application of imaging biomarkers has provided new insights into the mechanisms of damage
More informationDear Participants, Yours sincerely, Silvia Cristofanelli EXCEMED
EXCEMED Blended Education 16 th practice teaching course in MS knowledge Live intervention in 12-13 November 2018 Dear Participants, On behalf of EXCEMED, it is our pleasure to welcome you to the live
More informationMellen Center Approaches: Natalizumab
Cleveland Clinic Mellen Center for Multiple Sclerosis Treatment and Research 216.444.8600 Mellen Center Approaches: Natalizumab Who should be considered for Natalizumab therapy? In the phase II and phase
More informationFor HCPs Brain Health: Time Matters
For HCPs Brain Health: Time Matters Gavin Giovannoni Barts and The London Disclosures Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to clinical
More informationReview of methodological issues of clinical trials in multiple sclerosis
Journal of the Neurological Sciences 311 S1 (2011) S35 S42 Review of methodological issues of clinical trials in multiple sclerosis Xavier Montalban* Unitat de Neuroimmunologia, Centre d Esclerosi Múltiple
More informationHow do I choose the correct disease-modifying treatment?
Teaching Course 1 How do I choose the correct disease-modifying treatment? R.J. Fox (Cleveland, US) E. Havrdová (Prague, CZ) Chairs: 1 Starting an MS disease modifying therapy: individualised treatment
More informationCarolyn Taylor, M.D. Swedish Neuroscience Center
Carolyn Taylor, M.D. Swedish Neuroscience Center When should disease modifying therapy be discontinued in MS? Should we be using aggressive treatments earlier in the MS disease course and reserving the
More informationReactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis
Zurich Open Repository and Archive University of Zurich Main Library Strickhofstrasse 39 CH-8057 Zurich www.zora.uzh.ch Year: 2015 Reactivation of herpesvirus under fingolimod: A case of severe herpes
More informationFrom Emerging Agents to Biomarkers: Integrating Scientific Advances into MS Management
Special Supplement December 2013 Volume 15, Supplement 2 The Official Publication of the Consortium of Multiple Sclerosis Centers From Emerging Agents to Biomarkers: Integrating Scientific Advances into
More informationMRI in MS: the radiologist perspective
MS Preceptorship - Updating Knowledge in Multiple Sclerosis - June, 1-3 2010 Barcelona MRI in MS: the radiologist perspective Àlex Rovira Unidad de Resonancia Magnética Servicio de Radiología Hospital
More informationMedication Policy Manual. Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013
Medication Policy Manual Policy No: dru299 Topic: Tecfidera, dimethyl fumarate Date of Origin: May 16, 2013 Committee Approval Date: December 16, 2016 Next Review Date: December 2017 Effective Date: January
More informationNovartis real-world data at AAN confirms benefit of Gilenya on four key measures of disease activity in relapsing MS
Novartis International AG Novartis Global Communications CH-4002 Basel Switzerland http://www.novartis.com MEDIA RELEASE COMMUNIQUE AUX MEDIAS MEDIENMITTEILUNG Novartis real-world data at AAN confirms
More informationIs it time to target no evident disease activity (NEDA) in multiple sclerosis?
Is it time to target no evident disease activity (NEDA) in multiple sclerosis? Giovannoni, G; Turner, B; Gnanapavan, S; Offiah, C; Schmierer, K; Marta, M Licensed with a Creative Commons Attribution Non-Commercial
More informationNeurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy
Nicola De Stefano Neurology and Neurometabolic Unit Department of Neurological and Behavioral Sciences University of Siena Siena, Italy Declared receipt of honoraria or consultation fees from Novartis,
More informationPrimary Progressive MS. Predicting Progression. Alan J Thompson Director, UCL Institute of Neurology Queen Square
Primary Progressive MS Predicting Progression Alan J Thompson Director, UCL Institute of Neurology Queen Square Disclosures Alan J Thompson UCL Institute of Neurology Queen Square London, UK In compliance
More informationAchieving New Treatment Goals in Multiple Sclerosis Strategies for Initial Treatment Selection and Patient Engagement. Dayton, OH
A CME/CE-certified Symposium held in conjunction with the 2018 Annual Meeting of the CMSC Jointly provided by: In collaboration with: This program was supported by an educational grant from Sanofi Genzyme.
More informationThe Multiple Sclerosis Summit:
Special Supplement December 2011 Volume 13, Supplement 5 The Official Publication of the Consortium of Multiple Sclerosis Centers HIGHLIGHTS FROM The Multiple Sclerosis Summit: A Critical Appraisal to
More informationThe emergence of a new generation of multiple sclerosis
n reports n Emerging Oral Agents for Multiple Sclerosis Edward J. Fox, MD, PhD The emergence of a new generation of multiple sclerosis (MS) agents is likely to cause a significant shift in the MS treatment
More informationTechnology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta441
Daclizumab for treating relapsing remitting multiple sclerosis Technology appraisal guidance Published: 26 April 2017 nice.org.uk/guidance/ta441 NICE 2017. All rights reserved. Subject to Notice of rights
More informationORIGINAL ARTICLE EUROPEAN JOURNAL OF NEUROLOGY. Introduction
ORIGINAL ARTICLE Natalizumab improves ambulation in relapsing remitting multiple sclerosis: results from the prospective TIMER study and a retrospective analysis of AFFIRM N. Voloshyna a, E. Havrdova b,
More informationCurrent Advances In Multiple Sclerosis
Current Advances In Multiple Sclerosis Dr. Michael Namaka BSc Pharm; MSc Pharm; Ph D; EPP Professor; Neuro-immunologist College of Pharmacy and Medicine (Anesthesia & Rehab Medicine) University of Manitoba
More informationOptimizing Immunomodulatory Therapy with Interferon Beta in Patients with Multiple Sclerosis A Prospective Study
Optimizing Immunomodulatory Therapy with Interferon Beta in Patients with Multiple Sclerosis A Prospective Study Said Masri, MD; Andreas Blodau, MD; Norbert Zessack, PhD; Michael Lang, MD; for the High
More informationAPPENDIX D SASKATCHEWAN MS DRUGS PROGRAM
APPENDIX D SASKATCHEWAN MS DRUGS PROGRAM PROCEDURE FOR OBTAINING COVERAGE OF MS DRUGS UNDER THE DRUG PLAN Requests are initiated by a physician. The patient and physician complete the application form
More informationChoices. Disease modifying treatments. Read me
Choices Disease modifying treatments Read me Disease modifying treatments Disease modifying therapies (DMTs) are medications which modify the course of multiple sclerosis (MS) and are designed to reduce
More informationABSTRACT ORIGINAL RESEARCH. Ralf Gold. Gavin Giovannoni. J. Theodore Phillips. Robert J. Fox. Annie Zhang. Jing L. Marantz
Neurol Ther (2016) 5:45 57 DOI 10.1007/s40120-016-0042-8 ORIGINAL RESEARCH Sustained Effect of Delayed-Release Dimethyl Fumarate in Newly Diagnosed Patients with Relapsing Remitting Multiple Sclerosis:
More informationEmerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence
Emerging oral disease-modifying therapies in multiple sclerosis: a review of the latest clinical evidence Clin. Invest. (2011) 1(7), 1049 1058 Over the last two decades, patients have relied on the use
More informationEarliest MS: What Do We Know? RMMSC Education Summit May 12,2018. John R. Corboy, MD
Earliest MS: What Do We Know? RMMSC Education Summit May 12,2018 John R. Corboy, MD JRC has received grant support from PCORI, NMSS, Novartis, Biogen, and Med-Day. He receives compensation as the editor
More informationMultiple Sclerosis Treatment
Special Supplement September 2014 Volume 16, Supplement 5 The Official Publication of the Consortium of Multiple Sclerosis Centers Optimizing Efficacy and Adherence to Multiple Sclerosis Treatment 2014
More informationSample-size re-estimation in Multiple Sclerosis trials
Novartis Basel, Switzerland Sample-size re-estimation in Multiple Sclerosis trials Heinz Schmidli PSI Meeting on Sample Size Re-Estimation London, November 2, 2016 Outline Multiple Sclerosis Sample size
More informationAscertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era
Ascertaining the Role of the Primary Care Clinician in the Recognition and Management of Patients With Multiple Sclerosis in the Modern Era Edward J. Fox, MD, PhD MS Clinic of Central Texas Central Texas
More informationTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis(review)
Cochrane Database of Systematic Reviews Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis(review) Filippini G, Del Giovane C, Clerico M, Beiki
More informationORIGINAL CONTRIBUTION. Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study
ORIGINAL CONTRIBUTION Magnetic Resonance Imaging Effects of Interferon in the BENEFIT Study Integrated 2-Year Results Frederik Barkhof, MD, PhD; Chris H. Polman, MD, PhD; Ernst-Wilhelm Radue, MD; Ludwig
More informationDouglas L. Arnold 1,2, Peter A. Calabresi 3, Bernd C. Kieseier 4,5, Shifang Liu 5, Xiaojun You 5, Damian Fiore 5 and Serena Hung 5*
Arnold et al. BMC Neurology (2017) 17:29 DOI 10.1186/s12883-017-0799-0 RESEARCH ARTICLE Open Access Peginterferon beta-1a improves MRI measures and increases the proportion of patients with no evidence
More information